Lessons from LIBRETTO-431 Trial in RET+ NSCLC
An overview of data presented at ESMO 2023 on the LIBRETTO-431 trial of selpercatinib in RET+ NSCLC.
Source: ajmc.com
Page 31 - Nsclc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nsclc Today - Breaking & Trending Today
ALINA: Efficacy and Safety of Adjuvant Alectinib Versus Chemotherapy in Patients With Early-Stage ALK+ NSCLC
Benjamin Solomon, MBBS, PhD, FRACP, presents key data from the ALINA study investigating alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).
Source: onclive.com
FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLC
The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.
Source: onclive.com
Certain NSCLC Subgroups May Not Benefit From Immunotherapy
A comprehensive study exploring NSCLC subgroup responses to immunotherapy may help determine which patients are less likely to benefit from these agents.
Source: medscape.com
Dr Anders on the Rationale For Investigating Tivumecirnon Plus Pembrolizumab in NSCLC
Robert A. Anders, MD, PhD, discusses the rationale for investigating the use of tivumecirnon in patients with non–small cell lung cancer, as well as interim data from the dose-expansion portion of the phase 1/2 FLX475-02 study of this agent alone and in combination with pembrolizumab.
Source: onclive.com